博雅生物(300294.SZ)：人凝血因子Ⅸ药物临床试验获批准

Core Viewpoint - The company, Boya Bio-Pharmaceutical (300294.SZ), has received approval from the National Medical Products Administration for a clinical trial of coagulation factor IX, aimed at treating patients with hemophilia B [1] Group 1 - The approval allows the company to conduct clinical trials for treating bleeding in patients with coagulation factor IX deficiency [1]